Royalty Report: cardiac, Drugs, Pharmaceuticals – Collection: 3640

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • cardiac
  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Surgical
  • Diagnostic
  • Medical
  • Device
  • Supply
  • Enzymes

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3640

License Grant
The Company acquired the rights to Aggrastat® Injection (tirofiban hydrochloride) in the U.S. and itsterritories (Puerto Rico, Virgin Islands, and Guam).
License Property
Aggrastat®, a glycoprotein GP IIb/III a receptor antagonist, is used for the treatment of acute coronary syndrome (ACS) including unstable angina, which is characterized by chest pain when one is at rest, and non-Q-wave myocardial infarction (MI).  Aggrastat is a medicine which is used in prevention of a heart attack. Aggrastat contains tirofiban hydrochloride.
Field of Use
The Field of Use apply to the healthcare industry relating to the treatment of ACS.  Acute coronary syndrome (ACS) is usually one of three diseases involving the coronary arteries ST elevation myocardial infarction (30%), non ST elevation myocardial infarction (25%), or unstable angina (38%).

IPSCIO Record ID: 117698

License Grant
The parties co-promote INTEGRILIN in the United States and share any profits or losses. Outside of the United States, the Swiss Licensee markets INTEGRILIN exclusively.

With this amendment the Parties desire to modify their agreement to address such issue of sales allocation, and also with respect to the allocation of regulatory responsibilities in Canada, the manufacture and supply of Integrilin Product in Canada, and to set forth certain understandings regarding a Phase III clinical trial for Integrilin Product in the setting of acute myocardial infarction or AMI.

License Property
INTEGRILIN(R) (eptifibatide) Injection, is the only drug approved for use in both acute coronary syndromes and angioplasty procedures.
Field of Use
This agreement is for the pharmaceutical industry.
INTEGRILIN is indicated for the treatment of patients with an acute coronary syndrome and patients who undergo angioplasty procedures. The acute coronary syndrome indication includes patients with unstable angina and non-Q-wave myocardial infarction, whether they receive medical treatment or undergo angioplasty.

Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.

Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis.

IPSCIO Record ID: 8745

License Grant
Licensee signed an agreement with Japanese Licensor pertaining to the development and commercialization of adenosine for use in the treatment of acute ischaemic conditions of the heart, including acute myocardial infarction and open-heart surgery (formerly designated MEDR 640 programs) in the US and Canada.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 3248

License Grant
The parties have entered into a worldwide alliance. The Licensor has Agreements for the codevelopment and cocommercialization of AVAPRO/AVALIDE (irbesartan), an angiotensin II receptor antagonist indicated for the treatment of hypertension and diabetic nephropathy, which is copromoted in certain countries outside the U.S. under the tradename APROVEL/COAPROVEL and comarketed in certain countries outside the U.S. by the Licensor under the tradename KARVEA/KARVEZIDE; and PLAVIX (clopidogrel), a platelet aggregation inhibitor, which is copromoted in certain countries outside the U.S. under the tradename PLAVIX and comarketed in certain countries outside the U.S. by the Company under the tradename ISCOVER.
License Property
Clopidogrel bisulfate is a platelet aggregation inhibitor, which is approved for protection against fatal or non-fatal heart attack or stroke in patients with a history of heart attack, stroke, peripheral arterial disease or acute coronary syndrome.

AVAPRO/AVALIDE is an angiotensin II receptor blocker for the treatment of hypertension.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 7466

License Grant
The Licensor, government public health organization, hereby grants and Licensee accepts, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Development and commercialization of this technology will provide treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion and inflammation of the cardiovascular system. Development and commercialization of this technology will also provide treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.
Field of Use
Fields of Use of the Licensed Property is for prevention, treatment and mitigation of the following cardiovascular diseases peripheral artery disease (PAD), intermittent claudication, coronary artery disease (CAD), dyslipidemia, angina pectoris, myocardial infarction, atherosclerosis, coronary plaque stabilization, carotid atherosclerosis, congestive heart failure, cerebral stroke, post-ischemic reperfusion, inflammation of the cardiovascular system and the treatment of cardiovascular related peri and post-surgical inflammation associated with transplants.

IPSCIO Record ID: 372578

License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.

This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.

License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.

CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.

Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.

Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI.  Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks.  Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.

IPSCIO Record ID: 1006

License Grant
The US Licensee and Licensor, and, to the extent appropriate, the Licensee of the Netherlands Antilles, shall jointly collaborate in the Development and Commercialization of the Product and the Legal Activities, using Commercially Reasonable Efforts to Develop the Product, to achieve Legal Clearance, to bring the Product to the market in the U.S. Territory and to Commercialize the Product in the U.S. Territory.

Licensor grants to the Licensee of the Netherlands Antilles during the Term, an exclusive license, without the right to grant sublicenses, under Licensor IP and under Licensor's rights in the Joint Collaboration IP, to Develop, make, have made, use, sell, offer to sell, lease, import and export the Product in the U.S. Territory in the Field, and a non-exclusive license, with no right to grant sublicenses, under the Licensor's IP to make, have made, and use the Product in the Non-U.S. Territory, but only for the purposes of sale of the Product in or into the U.S. Territory; provided, however, that Licensor retains the right to practice, and to grant sublicenses, under Licensor IP and under Licensor's rights in the Joint Collaboration IP in the U.S. Territory in the Field to perform its obligations to the Licensees under this Agreement, including, without limitation, to conduct the Licensor activities under this Agreement and in the Annual Collaboration Plans and make and have made the Product in the U.S. Territory solely for the purposes of sales of the Product in the Field in those countries in the Non-U.S. Territory for which US Licensee does not, during the Non-U.S. Option Period, exercise the Non-U.S. Option, or if US Licensee exercises the Non-U.S. Option within the Non-U.S. Option Period, in those countries in the Non-U.S. Territory for which US Licensee and Licensor do not execute a Non-U.S. Territory Agreement either during the Initial Non-U.S. Territory Negotiation Period.

Licensor grants to either, but not both, of the Licensees the exclusive option to commence negotiations to obtain an exclusive license to Develop and Commercialize the Product in all or part of the Non-U.S. Territory.

The Company entered into a collaboration and License Agreement with another pharma to jointly develop and commercialize enoxaparin sodium injection, a generic version of Lovenox®, a low molecular weight heparin or LMWH.

License Property
Licensor is a biotechnology company with specific expertise in enoxaparin and the science of complex sugars, polysaccharides, their structures, their sequencing, and their characterization.

Product means injectable enoxaparin and any improved injectable form of enoxaparin for which Lovenox®, as defined in the relevant New Drug Application approved as of the Effective Date or any past or future Supplemental New Drug Applications, is the reference listed drug and for which an ANDA could be approved by the FDA, but specifically excluding any Improved Enoxaparin.  

Lovenox® (enoxaparin) is a low molecular weight heparin, or LMWH.

The patents include Rationally Designed Heparinases Derived from Heparinase I and II, and,  System and Method for Notating Polymers, and, Novel Method for Sequence Determination using NMR, and, Methods and Products Related to Low Molecular Weight Heparin, and, The Heparinase Gene from Flavobacterium Heparinum, and, Delta 4, 5 Glycuronidase And Uses Thereof.

Field of Use
Lovenox is used in prophylaxis and treatment of deep vein thrombosis, prophylaxis of ischaemic complications of unstable angina and non-Q-wave myocardial infarction, and the treatment of acute ST-segment elevation myocardial infarction.

The Field means the injectable administration of the Product for any and all medical indications.  Lovenox® (enoxaparin) is used to prevent and treat deep vein thrombosis.

IPSCIO Record ID: 28946

License Grant
The Israel Licensors hereby grants to the Licensee the exclusive, royalty-bearing right and license in the Territory under the Licensee's Intellectual Property (including, for clarity, a sublicense under the Sublicensed IP) to Develop, Manufacture and Commercialize Products for use in the Field.
License Property
The Licensor owns or controls certain intellectual property rights covering a liquid polymer composed of Sodium Alginate and Ca-D-Gluconate (designated by BioLineRx as “BL-1040”).  The Licensor is currently developing the Product (as defined below) as a medical device for the direct treatment of cardiac tissue following acute myocardial infarction.

Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.

BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.

BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heart’s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.

Field of Use
The Licensee is developing BCM for the prevention of cardiac remodeling, which often leads to congestive heart failure following an ST-segment elevated myocardial infarction, or STEMI.

IPSCIO Record ID: 4279

License Grant
The Licensee entered into a License Agreement with the Licensor.

The Licensee is obligated to pay a royalty on sales under the License for the Flocor Intellectual Property, also on sales under the License for Anti-Infectives Intellectual Property and on sales under the License for OptiVax Intellectual Property.

License Property
Upon attainment of certain milestones, which include regulatory approvals and first commercial sales, the Licensee may be obligated to pay fees of up to $8,000,000.
Field of Use
Flocor is an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury. Flocor has rheologic, cytoprotective, anti-adhesive and antithrombotic effects and has potential in the treatment of acute ischemic vascular disorders such as stroke and myocardial infarction (MI).

IPSCIO Record ID: 273380

License Grant
The University, with permissions as applicable, grant an exclusive, sublicensable license for the field of Use in the Territory to
—  practice under the Patent Rights
—  make, have made, use, lease, import, export and/or sell Licensed Products,
—  sell, use and/or practice Licensed Services.

The University grants a non-exclusive license to use Know-how for the Field of Use in the territory to
—  make, have made, use, lease and/or sell Licensed Products
—  sell, use and/or practice Licensed Services.

License Property
The University has rights to patents titles Reactive Oxygen Generating Enzyme and Inhibitor with Nitric Oxide Bioactivity and Uses Thereof, and, Composition for the Treatment and Prevention of Heart Disease and Methods of Using the Same.

The Phase II candidate and all other drugs in the portfolio are designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. All have a dual mechanism of action of inhibiting the creation of reactive oxygen radicals and concurrently providing nitric oxide in the failing heart. The therapeutic target is the ryanodine receptor, the ion channel in the heart that provides the calcium necessary for the heart to beat. The investigational drugs are believed to improve calcium cycling in the heart by acting on the ryanodine receptor to significantly improve the efficiency of heart contractility.

Field of Use
The field of use means all therapeutic uses for allopurinol, oxypurinol, ptcein-6-aldehyde and mixtures thereof, that are provided with a nitrate group thereon, as well as therapeutic uses for any combinations of these agents with nitrates or other NO donors.

The drug portfolio is to develop and commercialize certain of Licensee's proprietary cardiovascular drugs to treat heart failure.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.